Zoetis (NYSE: ZTS) to buy VitalRADS as teleradiology partnership goes in-house

Zoetis Inc. (NYSE: ZTS), the world’s largest animal health company by revenue, has entered into an agreement to acquire VitalRADS, the veterinary teleradiology and imaging services provider it has commercially partnered with since August 2025. The transaction, reported on 14 July 2026, converts an existing distribution and integration relationship into direct ownership of the specialist imaging workflow embedded in Zoetis’s ZoetisDx portal. Financial terms were not publicly disclosed at the time of the initial report, and the transaction is expected to be small in scale relative to Zoetis’s other 2026 activity, which includes the November 2025 acquisition of Veterinary Pathology Group in the United Kingdom and Ireland and the pending $160 million acquisition of Neogen Corporation’s animal genomics business.

The strategic significance is disproportionate to the likely deal size. Zoetis is consolidating the last third-party layer inside its Virtual Laboratory diagnostics offering at a moment when its companion animal franchise is under revenue pressure and its share price has retreated more than 50 percent from its 52-week high. The central question is whether tighter ownership of specialist imaging can materially strengthen the diagnostics moat that Zoetis has been building since its 2018 acquisition of Abaxis, or whether the deal is a small structural move that will not shift the near-term investment case.

What did Zoetis announce, and how does it convert a live commercial partnership into ownership?

The initial report describes Zoetis as intending to acquire VitalRADS outright, moving beyond the existing commercial partnership that has been in place since August 2025. Under that partnership, VitalRADS operated as the embedded teleradiology layer inside the Zoetis Virtual Laboratory, accessible to customers of the ZoetisDx portal without contracts or set-up fees. Board-certified specialists in radiology, cardiology, neurology and dentistry provided interpretation services across all common veterinary imaging modalities, including radiography, computed tomography, magnetic resonance imaging, ultrasonography including echocardiography, nuclear medicine, positron emission tomography and electrocardiography. STAT reports were offered in under one hour and routine reports typically within three hours. The acquisition would remove the commercial boundary between Zoetis and VitalRADS entirely, absorbing the specialist workforce, the VitalPACS image management system and the branded teleradiology offering into Zoetis’s global diagnostics organisation. The company has not, at the time of the initial report, disclosed a purchase price, payment structure or expected closing timeline. Full transaction detail is likely to be included in the 6 August 2026 second-quarter earnings release or in supplementary regulatory disclosure ahead of it.

Why does VitalRADS fit into Zoetis’s Virtual Laboratory diagnostics platform strategy?

Zoetis’s diagnostics strategy has evolved through a specific sequence of tuck-in acquisitions since the company was spun out from Pfizer in 2013. In 2018 it acquired Abaxis for approximately $2 billion, gaining the VetScan portfolio of point-of-care instruments. In 2019 it added Phoenix Central Laboratory and ZNLabs to enter reference laboratory services, followed by Ethos Diagnostic Science in 2020. In November 2025 it acquired Veterinary Pathology Group in the United Kingdom and Ireland to broaden multi-specialty diagnostic capacity. The VitalRADS partnership, and now the pending acquisition, closes the imaging services layer of that stack. Veterinary diagnostics has three primary modalities: in-clinic point of care using benchtop analysers, reference laboratory services for send-out samples, and specialist imaging interpretation for radiographs, computed tomography scans, magnetic resonance imaging studies and ultrasound. Zoetis had covered the first two through Abaxis and its reference lab acquisitions, but relied on external partnership for the third. Owning VitalRADS gives the company a single-vendor position across all three modalities, integrated through the same ZoetisDx portal login. For a mid-market veterinary practice, this simplifies both purchasing and workflow. Whether that simplification translates into a higher share of diagnostics spend at target clinics is the commercial test the acquisition will need to pass.

How does the acquisition change the competitive positioning against IDEXX and Antech in veterinary diagnostics?

The veterinary diagnostics market in North America is highly concentrated. IDEXX Laboratories, Inc. is the market leader across both point-of-care instruments and reference laboratory services, and its integrated model, tying laboratory samples and imaging referrals to the same billing relationship, is regarded as one of the strongest customer lock-in engines in animal health. Antech Diagnostics, part of Mars Petcare, operates a similar integrated model. Zoetis has historically been strong in point-of-care instruments through the Abaxis-derived VetScan line but has lagged both IDEXX and Antech in reference laboratory scale. The Virtual Laboratory concept, packaging point-of-care data, reference lab results and specialist consultation into a single portal, is Zoetis’s answer to that structural disadvantage. Owning the imaging interpretation layer strengthens that answer in one specific way: it removes the risk that VitalRADS could reroute referrals to a different portal or be acquired by an IDEXX competitor. In competitive terms, the acquisition is defensive as much as offensive. It secures a workflow anchor that would be difficult and expensive to replace. What it does not do is close the reference laboratory scale gap versus IDEXX. Zoetis’s own August 2025 partnership communications described VitalRADS as “our VitalRADS service,” suggesting the company already regarded it as a captive extension of the platform. The acquisition formalises that treatment.

What does the deal signal about Zoetis’s M&A tempo alongside VPG and the Neogen genomics acquisition?

The VitalRADS agreement is the third diagnostics-adjacent transaction Zoetis has moved on within roughly nine months. The November 2025 acquisition of Veterinary Pathology Group brought reference laboratory capacity across the United Kingdom and Ireland, an area of the international business where Zoetis had been underweight in send-out testing. In March 2026, Zoetis announced a definitive agreement with Neogen Corporation to acquire Neogen’s animal genomics business for $160 million, a transaction Neogen’s own disclosure indicated is expected to close by the end of the first half of its 2027 fiscal year. Neogen’s animal genomics business generated approximately $90 million in revenue in fiscal 2025 and gives Zoetis a genomics data and testing platform that fits its Precision Animal Health strategy. Together, the three transactions signal a management pattern. Zoetis is systematically consolidating adjacent diagnostic and precision-medicine capabilities that surround its core pharmaceuticals and vaccines franchises. The individual deals are small relative to a company generating $9.47 billion of revenue in 2025 and guiding to a range of $9.825 billion to $10.025 billion in 2026. Their aggregate significance is that they build a full-stack diagnostic offering that a single competitor would find difficult to replicate through organic development alone.

Why the Thrive Pet Healthcare ownership structure of VitalRADS matters for the transaction

Public reporting has established that VitalRADS is owned by Thrive Pet Healthcare, a private-equity backed veterinary hospital and services chain acquired by TSG Consumer Partners in April 2020 and subsequently rebranded from Pathway Vet Alliance in November 2021. Thrive completed a liability management transaction in March 2025 involving more than $1.7 billion of existing debt obligations, indicating financial pressure on the parent group even as VitalRADS’s operating model expanded. For Zoetis, the sale by Thrive of a discrete asset to a strategic buyer with obvious integration logic is the type of transaction that private equity sponsors typically execute to raise cash without unwinding the broader portfolio. The transaction terms have not been disclosed, but the ownership context suggests that Thrive was not a natural long-term owner of VitalRADS given the leveraged position of the parent. Zoetis is acquiring an asset that has already been operating as an extension of its own platform for close to a year, which limits execution risk. The employee base and technology stack should transfer intact provided customary retention arrangements are put in place. The most sensitive integration risk is the continuity of the board-certified specialist workforce, which is the source of clinical value in a teleradiology model.

How does the acquisition land against the current Zoetis stock reset and pending litigation backdrop?

The VitalRADS acquisition lands against a difficult period for Zoetis’s stock and its investor communication. Shares have declined approximately 39 percent year-to-date through mid-July, trading in the mid-$70 range against a 52-week high of $158.80 recorded earlier in the past 12 months. Reported reasons for the decline include a Q1 2026 report that disappointed on the companion animal segment, sustained analyst downgrades including a move to Hold by Argus, and a securities class action tied to disclosures during the period between 14 January 2025 and 6 May 2026. Multiple law firms have publicly reminded shareholders of the 27 July 2026 lead plaintiff deadline. Zoetis has also been removed from the Russell Top 200 and reclassified into the Russell Midcap Index, which prompted rebalancing outflows from index-based funds. Consensus analyst price targets have moved wider, with a 12-month average around $115 and individual targets ranging from $85 at Barclays to well over $150 at the more bullish end. In this backdrop, the VitalRADS acquisition is a small strategic signal that management continues to execute against its diagnostics platform ambition rather than pause it. It is not, however, a catalyst that can materially reset the stock’s trajectory on its own. The next major inflection point remains the 6 August 2026 second-quarter earnings release and the associated 2026 guidance update.

What should investors watch for on the Zoetis 6 August Q2 2026 earnings call?

Zoetis’s second-quarter 2026 earnings release, scheduled for 6 August, will provide the first opportunity to test whether the companion animal segment trajectory that troubled the first-quarter print has stabilised. Management will also be expected to provide detail on the VitalRADS transaction, including any deal terms not disclosed at the time of the initial announcement, integration timing, expected contribution to diagnostics revenue and any implications for the 2026 guidance range. The 2026 guidance frame set in February pointed to revenue of $9.825 billion to $10.025 billion, adjusted diluted earnings per share of $7.00 to $7.10, and organic operational revenue growth of 3 to 5 percent. Second-quarter delivery relative to that frame, together with any adjustment to the full-year range, will matter more for the near-term investment case than the VitalRADS acquisition itself. Investors should also expect commentary on the pending Neogen genomics closing, on the pace of integration of Veterinary Pathology Group in the United Kingdom and Ireland, and on the diagnostics segment competitive dynamics against IDEXX. The VitalRADS acquisition is a coherent piece in a larger strategy. The 6 August call is where the market will judge whether that strategy is producing enough underlying growth to justify the current valuation reset.

Key takeaways from Zoetis’s acquisition of VitalRADS imaging services

• Zoetis has announced the acquisition of VitalRADS, converting an August 2025 teleradiology partnership into direct ownership of the specialist imaging layer inside its ZoetisDx portal.
• Financial terms and closing timing were not publicly disclosed at the time of the initial report; further detail is expected around the 6 August 2026 second-quarter earnings release.
• VitalRADS provides board-certified specialist interpretation for radiography, computed tomography, magnetic resonance imaging, ultrasonography, nuclear medicine, PET/CT and electrocardiography.
• The transaction closes the specialist imaging layer of Zoetis’s Virtual Laboratory diagnostics platform, alongside point-of-care via Abaxis-derived VetScan and reference laboratory services via Phoenix Central Laboratory, ZNLabs, Ethos Diagnostic Science and Veterinary Pathology Group.
• The deal is the third diagnostics-adjacent transaction Zoetis has moved on within nine months, following the November 2025 VPG acquisition and the March 2026 announced $160 million acquisition of Neogen’s animal genomics business.
• Public reporting has established that VitalRADS is owned by Thrive Pet Healthcare, a TSG Consumer Partners-backed veterinary services chain that completed a $1.7 billion-plus liability management transaction in March 2025.
• The competitive read positions the acquisition as a defensive workflow anchor against IDEXX Laboratories and Antech Diagnostics rather than a reference laboratory scale response.
• Zoetis shares are down approximately 39 percent year-to-date through mid-July 2026, trading in the mid-$70 range against a 52-week high of $158.80.
• A securities class action tied to disclosures between 14 January 2025 and 6 May 2026 remains open, with a 27 July 2026 lead plaintiff deadline.
• Full-year 2026 guidance remains at revenue of $9.825 billion to $10.025 billion and adjusted diluted EPS of $7.00 to $7.10, with the 6 August earnings release providing the next material update.